Nature Reviews Clinical Oncology最新文献

Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy - a full-circle moment for nasopharyngeal cancer. 液体活检告知新辅助化疗期间的辅助决策-鼻咽癌的一个完整的循环时刻。

IF 82.2 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-05-06 DOI: 10.1038/s41571-026-01157-8

W K Jacky Lam, Brigette B Y Ma

引用次数: 0

The transformative role of SBRT in the management of spinal metastases. SBRT在脊柱转移治疗中的变革作用。

IF 82.2 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-05-05 DOI: 10.1038/s41571-026-01152-z

K Liang Zeng, Pejman Jabehdar Maralani, Michael Hardisty, Hanbo Chen, Jay Detsky, Deepak Dinakaran, Hany Soliman, Chia-Lin Tseng, Jeremie Larouche, Jetan Badhiwala, Elizabeth David, Katarzyna J Jerzak, Amit Singnurkar, Chris Heyn, Cari Whyne, Mark Ruschin, Arjun Sahgal

{"title":"The transformative role of SBRT in the management of spinal metastases.","authors":"K Liang Zeng, Pejman Jabehdar Maralani, Michael Hardisty, Hanbo Chen, Jay Detsky, Deepak Dinakaran, Hany Soliman, Chia-Lin Tseng, Jeremie Larouche, Jetan Badhiwala, Elizabeth David, Katarzyna J Jerzak, Amit Singnurkar, Chris Heyn, Cari Whyne, Mark Ruschin, Arjun Sahgal","doi":"10.1038/s41571-026-01152-z","DOIUrl":"https://doi.org/10.1038/s41571-026-01152-z","url":null,"abstract":"<p><p>Spinal metastases can cause disabling pain and neurological deterioration and have historically been treated with palliative intent and conventional external beam radiotherapy (cEBRT). A fundamental shift away from the short-term palliative goals associated with cEBRT has taken place over the past two decades following the availability of stereotactic body radiotherapy (SBRT). This technique has enabled durable pain relief and local control owing to the ability to precisely deliver high radiation doses across typically up to five fractions, with level 1 evidence supporting superior complete pain response rates and local tumour control compared with cEBRT. The development of spinal SBRT has also resulted in greater multidisciplinary collaboration, with neuroradiologists, spinal surgeons, interventional radiologists, biomechanical engineers, medical physicists, medical oncologists and radiation oncologists working together with the common goal of improving our understanding of the pathophysiology and treatment of spinal metastases. As a result, substantial gains have been realized in refining patient selection and treatment sequencing, and particularly the development of less-invasive surgical procedures. In this Review, we summarize the development and role of SBRT in the management of spinal metastases.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":82.2,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147840682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synergistic integration of regional and systemic therapies in uveal melanoma. 葡萄膜黑色素瘤的局部和全身治疗的协同整合。

IF 82.2 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-04-29 DOI: 10.1038/s41571-026-01155-w

Shaheer A Khan, Richard D Carvajal

引用次数: 0

Emerging trends in the global burden of colorectal cancer. 全球结直肠癌负担的新趋势。

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-04-28 DOI: 10.1038/s41571-026-01149-8

David J Lee,Aparna Parikh,Bhawna Sirohi,Yin Cao,Andrew T Chan

{"title":"Emerging trends in the global burden of colorectal cancer.","authors":"David J Lee,Aparna Parikh,Bhawna Sirohi,Yin Cao,Andrew T Chan","doi":"10.1038/s41571-026-01149-8","DOIUrl":"https://doi.org/10.1038/s41571-026-01149-8","url":null,"abstract":"Globally, colorectal cancer (CRC) is the third most frequently diagnosed cancer and the second leading cause of cancer-related deaths, although these epidemiological patterns show substantial geographical variation. In this Review, we discuss the emerging global patterns of CRC incidence, which historically has been the highest among Western, high-income countries but is now increasing globally beyond these regions. This rise has mainly been driven by early-onset CRC - that is, cancers diagnosed in individuals aged <50 years. A birth cohort effect beginning with individuals born in the 1960s indicates that factors beyond genetic susceptibility or changes in screening practice underlie this increase. A changing landscape of established and emerging risk factors occurring worldwide has been proposed to underlie these epidemiological trends in CRC. Hypothesized risk factors include dietary and lifestyle aspects, shifts in the gut microbiota and the rise in environmental contaminants associated with the rapid urbanization occurring globally. Substantial advances in the characterization of genomic and epigenomic profiles of CRCs as well as their gut microbiomes not only hold potential for providing insight on the aetiology of this disease but could also be leveraged for early detection and interception strategies. The under-representation of non-Western populations in these studies, however, greatly limits progress and, if not addressed, could widen the existing gaps in global CRC prevention and control.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"35 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147754598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The clinical landscape of HIF2α inhibitors in oncology. 肿瘤中HIF2α抑制剂的临床前景。

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-04-28 DOI: 10.1038/s41571-026-01145-y

Eddy Saad,Marc Machaalani,David F McDermott,Toni K Choueiri

{"title":"The clinical landscape of HIF2α inhibitors in oncology.","authors":"Eddy Saad,Marc Machaalani,David F McDermott,Toni K Choueiri","doi":"10.1038/s41571-026-01145-y","DOIUrl":"https://doi.org/10.1038/s41571-026-01145-y","url":null,"abstract":"Hypoxia-inducible factor 2α (HIF2α; also known as endothelial PAS domain-containing protein 1) had long been considered an undruggable transcription factor until the discovery of an allosteric pocket within its PAS-B domain enabled the development of selective small-molecule antagonists. Belzutifan, the first-in-class HIF2α inhibitor, has since demonstrated substantial efficacy in patients with von Hippel-Lindau (VHL) disease-associated tumours, sporadic clear-cell renal cell carcinoma (ccRCC), and pheochromocytoma or paraganglioma, thereby validating HIF2α as a therapeutic target in patients with cancer. In this Review, we summarize the biology of the VHL-HIF signalling pathway, the structural basis for HIF2α druggability and the clinical milestones leading to the multiple regulatory approvals of belzutifan. We also highlight emerging data on other small-molecule inhibitors, RNA interference approaches and indirect modulators that have the potential to expand the scope of HIF pathway suppression. Combination strategies offer opportunities to enhance efficacy and overcome resistance; however, key challenges remain, including the identification of predictive biomarkers, mechanisms of primary and acquired resistance, and optimal management approaches for on-target toxicities such as anaemia and hypoxia. Finally, we discuss the increasing potential of HIF2α inhibition beyond kidney cancer, including its role in hypoxia-adapted malignancies, and outline priorities for future translational and clinical research.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"137 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147754600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Did ATOMIC really improve on the standard of care for mismatch repair-deficient colon cancer? ATOMIC真的提高了错配修复缺陷结肠癌的护理标准吗？

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-04-23 DOI: 10.1038/s41571-026-01154-x

Javier-David Benitez-Fuentes,Deme Karikios,Bishal Gyawali

引用次数: 0

Systemic induction therapy and the expanding frontier of bladder preservation in MIBC. 全身诱导治疗与MIBC患者膀胱保存的拓展。

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-04-22 DOI: 10.1038/s41571-026-01153-y

Laura S Mertens,Ashish M Kamat

引用次数: 0

Time as an unmeasured 'dose' in oncology: introducing time budgeting as a design principle for cancer care. 肿瘤学中时间作为不可测量的“剂量”：引入时间预算作为癌症治疗的设计原则。

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-04-21 DOI: 10.1038/s41571-026-01151-0

Sunil Shrestha,Pratik Khanal,Enrique Soto-Perez-de-Celis

引用次数: 0

OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC. 一线datopotamab deruxtecan治疗晚期TNBC的OS获益

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-04-15 DOI: 10.1038/s41571-026-01150-1

Diana Romero

引用次数: 0

Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders. car - T细胞治疗后淋巴细胞增生性疾病的频谱、病理生物学、机制见解和诊断挑战。

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2026-04-15 DOI: 10.1038/s41571-026-01147-w

Alaa Ali,Metin Ozdemirli,Mark P Hamilton,Michael D Jain

{"title":"Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders.","authors":"Alaa Ali,Metin Ozdemirli,Mark P Hamilton,Michael D Jain","doi":"10.1038/s41571-026-01147-w","DOIUrl":"https://doi.org/10.1038/s41571-026-01147-w","url":null,"abstract":"Chimeric antigen receptor (CAR) T cell therapy is now widely used for the treatment of various haematological malignancies, with emerging applications in solid tumours and autoimmune diseases. Alongside its demonstrated clinical activity, this therapeutic modality has a toxicity profile that differs from those associated with traditional cytotoxic therapies, other immunotherapies, and even other cell therapy approaches such as allogeneic haematopoietic stem cell transplantation. One increasingly recognized yet poorly understood complication is the development of post-CAR T cell therapy lymphoproliferative and lymphomatous disorders, which have a clinical and biological spectrum that remains incompletely characterized. These rare events include both CAR-transgene-positive and transgene-negative lymphomas with variable and sometimes overlapping clinical features. Causal attribution is difficult, given that these proliferations often emerge in the context of clonal haematopoiesis, inflammatory or infectious triggers, immune suppression and/or viral reactivation. In this Review, we synthesize the growing body of evidence on post-CAR T cell therapy lymphoproliferative disorders, drawing on the limited but increasing number of well-characterized cases. We outline the spectrum of lymphoproliferations described so far, highlight recurrent pathological and molecular features, and discuss factors that might promote clonal expansion or transformation, including pre-existing clonal haematopoiesis, dysregulated signalling pathways, inflammatory stimuli and, rarely, CAR-transgene vector integration. A clearer framework for these disorders might improve early recognition, guide diagnostic evaluation, support treatment decision-making, facilitate classification and consensus-building efforts, and inform future mechanistic studies and pharmacovigilance efforts.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"45 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147684704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0